## Ajanta Pharma Limited (AJANTPHARM) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Ajanta Pharma Limited (AJANTPHARM) is a pharmaceutical company listed on the National Stock Exchange of India (NSE) since May 29, 2000.  It operates within the Pharmaceuticals & Biotechnology sector, focusing on the manufacturing and marketing of pharmaceutical products.  While specific market positioning within the sector requires further research beyond the provided data, its presence on the NSE indicates a significant player in the Indian pharmaceutical market.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹2,819.90       |                                                                      |
| Percentage Change (PChange) | -1.94%          | Negative change indicates a recent price decline.                     |
| Pre-Open Activity          | Mixed           | Pre-open orders show some buying interest but limited volume (24 shares). |
| Week High                    | ₹3,485.00       | Significant high compared to the current price, suggesting recent volatility. |
| Week Low                     | ₹1,850.25       | Significant low compared to the current price, further indicating volatility. |
| VWAP                        | ₹2,877.70       | Volume Weighted Average Price slightly higher than the current price. |
| Sector PE                   | 41.05           | Industry average Price-to-Earnings ratio.                            |
| Symbol PE                   | 41.05           | Ajanta Pharma's Price-to-Earnings ratio, indicating valuation relative to earnings. |
| Delivery Percentage         | 52.83%          | Moderate delivery percentage; a significant portion of trades were delivery-based. |
| Market Depth                | Low             | Order book data shows low buy and sell quantities at various price points.  |


**3. Financial Performance:**

The provided financial data shows a consistent profit after tax (PAT) and earnings per share (EPS) over the past five quarters, although the figures are unaudited for the most recent quarters.  However, it's crucial to note that all reported figures represent *profits*, not losses as the data initially suggests.  The data needs clarification as "proLossAftTax" is used inconsistently.  Assuming this is a data entry error and the values represent profit, the analysis continues.

| Quarter      | Revenue (₹) | Expenditure (₹) | Profit After Tax (₹) | EPS (₹) |
|--------------|-------------|-----------------|-----------------------|---------|
| Q1 2024      | 95,975      | 73,381          | 16,269                 | 12.92   |
| Q2 2024      | 110,564     | 79,508          | 23,603                 | 18.77   |
| Q3 2024      | 116,925     | 86,005          | 23,498                 | 18.75   |
| Q4 2023      | 109,902     | 79,388          | 22,015                 | 17.48   |
| Q3 2023      | 99,734      | 70,684          | 21,236                 | 16.87   |


**Key Financial Ratios:**  Further analysis requires additional financial statements (balance sheet, cash flow statement) to calculate key ratios like Return on Equity (ROE), Debt-to-Equity ratio, and current ratio.  The provided data is insufficient for a comprehensive ratio analysis.

**4. Corporate Actions and Announcements:**

Ajanta Pharma has undertaken several corporate actions recently, including interim dividends and buybacks.  The most recent interim dividend of ₹28 per share (ex-date November 6, 2024) is a significant event.  The frequency of buybacks suggests active management of shareholder value.  Announcements regarding loss/duplicate share certificates are administrative and do not significantly impact the stock's performance.

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023  | 66.21                        | 33.79      | 0.00                           | 100.00    |
| 31-Dec-2023  | 66.21                        | 33.79      | 0.00                           | 100.00    |
| 31-Mar-2024  | 66.21                        | 33.79      | 0.00                           | 100.00    |
| 30-Jun-2024  | 66.27                        | 33.73      | 0.00                           | 100.00    |
| 30-Sep-2024  | 66.26                        | 33.74      | 0.00                           | 100.00    |

Promoter holding remains relatively stable, indicating strong management confidence.

**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low.  The high annualized volatility (37.25%) further confirms this.  The risk-reward profile is skewed towards higher risk due to this volatility.  Further risk assessment requires analysis of macroeconomic factors affecting the pharmaceutical industry and Ajanta Pharma's specific competitive landscape.

**7. Advantages of Buying the Stock:**

* **Consistent Profitability:**  Ajanta Pharma has shown consistent profitability over the past five quarters (assuming the data error is corrected).
* **Regular Dividends and Buybacks:**  The company actively returns value to shareholders through dividends and buybacks.
* **Stable Promoter Holding:**  High and stable promoter holding suggests confidence in the company's future.

**8. Disadvantages and Risks:**

* **High Volatility:**  The stock price is highly volatile, posing significant risk to short-term investors.
* **Limited Market Depth:**  Low market depth could lead to difficulty in executing large trades at desired prices.
* **Dependence on External Factors:**  The pharmaceutical industry is susceptible to regulatory changes and macroeconomic conditions.


**9. Investment Horizon Recommendations:**

* **Short-Term (less than 3 months): Hold.** The recent price decline and high volatility make a short-term buy risky.  Holding is recommended until clearer price direction emerges.

* **Medium-Term (3 to 12 months): Hold/Buy (Cautiously).**  The consistent profitability and upcoming dividend make it a cautiously optimistic medium-term prospect.  However, volatility remains a concern.  A buy decision should be based on further price consolidation and reduced volatility.

* **Long-Term (1 year and beyond): Buy (Cautiously).**  The fundamentals, including consistent profitability and stable promoter holding, suggest long-term potential.  However, investors should be prepared for potential volatility and carefully monitor the company's performance and industry trends.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* **Financial Health (out of 10): 7** (Consistent profitability, but limited ratio analysis due to data limitations)
* **Market Performance (out of 10): 5** (High volatility, moderate delivery percentage, low market depth)
* **Volatility and Risk (out of 10): 4** (High volatility is a significant risk factor)
* **Corporate Actions & Governance (out of 10): 8** (Regular dividends and buybacks, stable promoter holding)
* **Shareholding Patterns (out of 10): 7** (Stable promoter holding)

**Analysis Score (out of 10): 8**

* **Data Utilization (out of 10): 9** (Most data points were used effectively)
* **Analysis Clarity (out of 10): 8** (Analysis is clear and well-structured)
* **Professional Formatting (out of 10): 9** (Report is professionally formatted)


**11. Professional Recommendation Summary:**

Ajanta Pharma presents a mixed investment picture.  While the company demonstrates consistent profitability and strong corporate governance, the high volatility and limited market depth introduce significant risk.  A cautious approach is recommended, with a "Hold" strategy for the short-to-medium term, and a cautiously optimistic "Buy" for the long term, contingent on further price consolidation and reduced volatility.  Investors should conduct thorough due diligence and consider their individual risk tolerance before making any investment decisions.  The analysis is limited by the incomplete financial data provided.  A more comprehensive analysis would require access to complete financial statements and industry benchmarks.
